The addition of vildagliptin to metformin prevents the elevation of interleukin 1 ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic ef...

Source: Cardiovascular Diabetology - May 22, 2017 Category: Cardiology Authors: Arwa Younis, Dana Eskenazi, Ronen Goldkorn, Jonathan Leor, Nili Naftali-Shani, Enrique Z. Fisman, Alexander Tenenbaum, Ilan Goldenberg and Robert Klempfner Source Type: research